Cargando…

Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGF(c )chimeric protein targeting tissue factor

BACKGROUND: Cervical cancer continues to be an important worldwide health problem for women. Up to 35% of patients who are diagnosed with and appropriately treated for cervical cancer will recur and treatment results are poor for recurrent disease. Given these sobering statistics, development of nov...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cocco, Emiliano, Varughese, Joyce, Buza, Natalia, Bellone, Stefania, Glasgow, Michelle, Bellone, Marta, Todeschini, Paola, Carrara, Luisa, Silasi, Dan-Arin, Azodi, Masoud, Schwartz, Peter E, Rutherford, Thomas J, Pecorelli, Sergio, Lockwood, Charles J, Santin, Alessandro D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3141777/ https://www.ncbi.nlm.nih.gov/pubmed/21693061 http://dx.doi.org/10.1186/1471-2407-11-263

Ejemplares similares

hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma
por: Cocco, E, et al.
Publicado: (2010)

Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody
por: Raji, Rhoda, et al.
Publicado: (2011)

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
por: Todeschini, P, et al.
Publicado: (2011)

Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy
por: Bellone, S, et al.
Publicado: (2012)

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
por: El-Sahwi, K, et al.
Publicado: (2010)

Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer
por: Cocco, Emiliano, et al.
Publicado: (2010)

Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer
por: Cocco, E, et al.
Publicado: (2009)

T-DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo
por: English, Diana P, et al.
Publicado: (2014)

Tissue factor is an angiogenic-specific receptor for factor VII-targeted immunotherapy and photodynamic therapy
por: Hu, Zhiwei, et al.
Publicado: (2016)

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro
por: Ferrari, Francesca, et al.
Publicado: (2015)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
por: Santin, Alessandro D., et al.
Publicado: (2016)

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo
por: Cocco, Emiliano, et al.
Publicado: (2016)

Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy
por: Bellone, S, et al.
Publicado: (2013)

Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan
por: Zeybek, Burak, et al.
Publicado: (2020)

Robotic Versus Abdominal Hysterectomy for Very Large Uteri
por: Silasi, Dan-Arin, et al.
Publicado: (2013)

Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells
por: Yokota, N, et al.
Publicado: (2009)

Tissue Factor–Factor VII Complex As a Key Regulator of Ovarian Cancer Phenotypes
por: Koizume, Shiro, et al.
Publicado: (2015)

The effect of Warfarin and factor VII on tissue procoagulant activity and pulmonary seeding.
por: Francis, J. L., et al.
Publicado: (1992)

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo
por: Schwab, C L, et al.
Publicado: (2014)

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer
por: Perrone, Emanuele, et al.
Publicado: (2020)

Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo
por: Perrone, Emanuele, et al.
Publicado: (2020)

Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
por: Roque, Dana M., et al.
Publicado: (2022)

Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer
por: Santin, A D, et al.
Publicado: (2002)

Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas
por: Lopez, Salvatore, et al.
Publicado: (2020)

Extracellular vesicles from amniotic fluid, milk, saliva, and urine expose complexes of tissue factor and activated factor VII
por: Hu, Yong, et al.
Publicado: (2022)

Fibronectin at select sites binds multiple growth factors (GF) and enhances their activity: expansion of the collaborative ECM-GF paradigm
por: Zhu, Jia, et al.
Publicado: (2013)

Associated characteristics and impact on recurrence and survival of free-floating tumor fragments in the lumen of fallopian tubes in Type I and Type II endometrial cancer
por: Albright, Benjamin B., et al.
Publicado: (2018)

Novel factor VII gene mutations in six families with hereditary coagulation factor VII deficiency
por: Zhang, Xiaoyu, et al.
Publicado: (2021)

Mutations of TFPI-binding exosites on factor VII cause bleeding phenotypes in factor VII deficiency
por: Seanoon, Karnsasin, et al.
Publicado: (2022)

Lower S-adenosylmethionine levels and DNA hypomethylation of placental growth factor (PlGF) in placental tissue of early-onset preeclampsia-complicated pregnancies
por: Heil, Sandra G., et al.
Publicado: (2019)

A Simple Approach to Specimen Retrieval via Posterior Colpotomy Incision
por: Clark, Lindsay E., et al.
Publicado: (2015)

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma
por: Pelligra, Silvia, et al.
Publicado: (2020)

Identification of Optimal Reference Genes for Gene Expression Normalization in a Wide Cohort of Endometrioid Endometrial Carcinoma Tissues
por: Romani, Chiara, et al.
Publicado: (2014)

Newly diagnosed congenital factor VII deficiency and utilization of recombinant activated factor VII (NovoSeven(®))
por: Bartosh, Nicole S, et al.
Publicado: (2013)

Vaginal Cuff Dehiscence in Robotic-Assisted Total Hysterectomy
por: Kashani, Shabnam, et al.
Publicado: (2012)

Robotic-Assisted Laparoscopic Hysterectomy: Outcomes in Obese and Morbidly Obese Patients
por: Gallo, Taryn, et al.
Publicado: (2012)

Increased serum 1,25-dihydroxyvitamin D levels in gynecologic cancer patients with Post-Acute-Covid-Sequela (PASC)/Long COVID
por: Bellone, Stefania, et al.
Publicado: (2023)

Acquired deficiency of coagulation factor VII
por: da Silva, Vanessa Afonso, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_i36bhpki0og5iepuh48fhkj0bk